On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts

  • Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor
  • TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes
  • There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such data is difficult to generate quickly.
  • Predictive Oncology has access to historical data that competitors need at least five years to develop, which presents a multi-million-dollar market opportunity

The global cancer diagnostics market was valued at $144.4 billion in 2018 and is expected to grow at a 7.0% CAGR over the next six years on the back of increasing prevalence of oncologic cases, rapid technological advancement, and rising demand for effective screening tests. Within this broader cancer market, the Patient Derived Xenograft (PDx) segment, which involves a personalized approach to cancer treatment, was valued at $ 77.4 million in 2017 and is expected to grow at a CAGR of 16.7%, reaching $167.6 million by 2022. The driving forces behind this growth include the increasing demand for personalized medicine as well as public and private commitment to cancer research coupled with the growing R&D activities in the pharmaceutical industry.

TumorGenesis, a subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), was established in 2018 to tap into this lucrative market with its unique way to capture and culture cancer cells and screen drug combinations for personalized cancer treatment. The parent company, Predictive Oncology, aims to deliver cutting-edge services for the oncology research and profiling market.

The problem with traditional cancer research is that it relies on the procedure whereby cancer cells need to be immortalized before they can be multiplied into colonies, which are then used in further research. Immortalization, however, renders all the cells identical, resulting in homogeneous cancer cell colonies, a characteristic that is far from true for the cancer cells found in human patients. What the scientific community now realizes is that cancer tissue comes as a mixture of rapidly mutating cell variants with unpredictable behavior, which means that traditional models are not sufficiently reliable.

However, there’s a paradigm shift occurring in cancer research as Patient Derived Xenografts (PDx) cancer models are developed. These are models where the cells from a patient’s tumor are taken, cultured, and then implanted into immunodeficient mice and rats – but the challenge is to keep the cells uncompromised during the process. TumorGenesis is part of this novel line of cutting-edge research as the company developed a proprietary technology that enables tumors to be grown in the lab in a medium that tricks the tumor cells into thinking they are still in the body.

TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer cell colonies in a way that will not compromise their integrity – a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more accurate identification of tumors and the development of patient-specific treatment options. The company expects this revolutionary product to hit the market by the end of the year.

What is unique with TumorGenesis’ state-of-the-art approach to cancer research is that the company has already developed 25 validated ovarian cancer cell types that mature into uncompromised tumor colonies not only in vitro but in rats and mice, too – a formidable accomplishment as 15 out of 25 cell lines represent around 90% of all ovarian cancers discovered so far, including those most virulent and deadly.

The company is also at the forefront of immunoncological research as it developed the proprietary technology called Ovarian Cancer Kit that uses the patient’s immune system to identify cancer cell types, inhibit their growth, and categorize their response to drug treatment. These developments are possible as the parent company POAI holds the world’s largest database of tumor drug response profiles and other multi-omic data, which they leverage to develop Artificial Intelligence-powered predictive models of therapy response. This enables more rapid target drug identification and significantly improves the drug approval rates, giving the company an unrivaled competitive edge.

POAI intends to make an impact in the precision medicine business with the goal of monetizing its assets within 18 months to reach a valuation comparable to its peers of $250 million. Unlike most competitors, the company has access to historical data on clinical outcomes and can generate value to pharmaceuticals much faster, while competitors must wait at least five years for the data. With a current valuation of only about $13 million, POAI is a compelling opportunity in the rapidly growing oncology outsourcing market, estimated to exceed $24 billion by 2026.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

September 25, 2020

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, […]

Rotate your device 90° to view site.